Antitumor Activity of Rapamycin in Glioblastoma Patients
Author Information
Author(s): Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J
Primary Institution: University of California, Los Angeles
Hypothesis
What is the effect of rapamycin on patients with recurrent PTEN-deficient glioblastoma?
Conclusion
The study found that rapamycin showed antitumor activity in some patients with recurrent PTEN-deficient glioblastoma.
Supporting Evidence
- 50% of patients showed suppression of mTOR correlated with inhibition of tumor cell proliferation.
- Preclinical data did not predict the response rates observed in the trial.
- Activation of feedback loops may explain the diminished response rate in some patients.
Takeaway
Doctors tested a medicine called rapamycin on patients with a type of brain cancer, and it helped some of them feel better.
Methodology
Patients with recurrent PTEN-deficient glioblastoma were treated with rapamycin for one week, underwent resection, and continued therapy until tumor recurrence.
Limitations
Only 50% of patients responded to treatment, indicating variability in effectiveness.
Participant Demographics
Patients had recurrent glioblastoma with known PTEN loss.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website